Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL), a clinical-stage biopharmaceutical company focused on cancer cell therapies, announced its participation in two investor conferences. The Citi 2023 Virtual Oncology Leadership Summit includes a fireside chat on February 21, 2023, at 10:00 am ET. Additionally, Gracell will host a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 9:30 am ET, followed by one-on-one meetings. Webcasts of both events will be available on their website for 90 days.

SAN DIEGO, Calif., and SUZHOU, China and SHANGHAI, China, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in two upcoming investor conferences.

Citi 2023 Virtual Oncology Leadership Summit
Fireside Chat: February 21^st at 10:00 am ET

H.C. Wainwright Cell Therapy Virtual Conference
Fireside Chat: February 28^th at 9:30 am ET
One-on-one meetings: Tuesday, February 28^th, 2023

A webcast of the presentations will be available on the News and Events  section of the Company's website. A replay of the webcast will be available for 90 days following the event. For more information, please visit ir.gracellbio.com.

About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART^TM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit http://www.gracellbio.com/. Follow @GracellBio on LinkedIn.

FAQ

What is Gracell Biotechnologies' participation in investor conferences in February 2023?

Gracell will participate in the Citi 2023 Virtual Oncology Leadership Summit on February 21, 2023, and the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023.

When will the fireside chats for Gracell take place?

The fireside chat at the Citi 2023 Virtual Oncology Leadership Summit is on February 21, 2023, at 10:00 am ET, and the one at the H.C. Wainwright Cell Therapy Virtual Conference is on February 28, 2023, at 9:30 am ET.

How can I access the webcasts of Gracell's presentations?

Webcasts of Gracell's presentations can be accessed on their website and will be available for 90 days after the events.

What technologies is Gracell Biotechnologies developing?

Gracell is developing cell therapies using its FasTCAR and TruUCAR technology platforms, focusing on overcoming challenges in conventional CAR-T therapies.